OM#5 – FINAL

18 patients with ALS were treated by delivering CNS10-NPC-GDNF unilaterally into the lumbar spinal cord. The primary objective of safety was met and the cell product was found to survive in the spinal cord and release GDNF for up to 3.5 years.